Page 13 - Pharma Companies

PE firm Multiples picks up 9.3% stake in BDR Pharma for Rs 685 cr

Multiples is the first private equity (PE) investor in BDR Pharma

GlaxoSmithKline Pharma reports consolidated net loss of Rs 55 crore

Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major said in a regulatory filing

Moderna CFO exits day after taking charge as former employer launches probe

Jorge Gomez previously worked for dental products maker Dentsply Sirona, which last month fired its CEO.

Sanofi India: Strong balance sheet, high cash reserves positives for stock

Products in the price control list and growth of the non-power brand portfolio will be key monitorables

Cost pressure likely to weigh on pharma companies' margins in Q4

Among Indian firms, Edelweiss feels that Cipla (respiratory) and Sun Pharma (specialty) are better placed to tide the price erosion

India hopes Hyderabad 'pharma city' will break China's grip on industry

India's ability to secure not just its own drug supply but that of Africa, the Americas and Europe is at stake

Cadila Pharma launches world's first novel 3-dose vaccine against rabies

The three-dose vaccine, named as 'ThRabis', is a recombinant nano-particle based G protein vaccine which is prepared using Virus-like Particle technology

Top pharma firms to hike R&D spend next 5 yrs as mkt eyes $130 bn revenue

Industry captains feel pandemic has opened up opportunities for the sector in India to emerge as a second source of raw material and finished products, after China

Global community can tap India's Covid vaccine capacity, say firms

Bharat Biotech MD Krishna Ella said India now has four BSL-4 containment facilities, equal to that of the UK.

Contract drug maker V-Ensure gets Rs 130 cr from Investcorp, Tanas Capital

Founded in 2010, V-Ensure is into specialty pharmaceutical formulations focused on complex generics for regulated markets

Purdue's Sacklers boost opioid settlement offer up to $6 billion

As part of the deal, Purdue will hand over nearly all of its assets to the states, cities and counties that are suing the drugmaker over its handling of the pain killer OxyContin

Mankind Pharma acquires two derma and respiratory brands from Dr Reddy's

Mankind Pharma to take over manufacturing, marketing and distribution of both products in India; entire integration and transition of the brands likely to be completed by March

Macleods Pharma files DRHP for second largest IPO by drug co at Rs 5,000 cr

It is entirely an offer for sale or OFS, company won't receive any of the proceeds

Strides Pharma records net loss of Rs 122 cr in Q3, revenue drops 5%

Company expects growth momentum in the US to pick up in coming quarters driven by new product launches

Pricing trend, launches, stability of growth boosters for Dr Reddy's

Near-term outlook and valuation are expected to support the stock price

Cipla Q3 PAT dips 2.6% at Rs 729 crore

Drug major Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021. The Mumbai-based company had posted a consolidated profit after tax (PAT) of Rs 748 crore in the October-December quarter of 2020-21 fiscal. Total revenue from operations, however, rose by 6 per cent to Rs 5,479 crore in the third quarter as compared with Rs 5,169 crore in the same period of last fiscal, Cipla said in a regulatory filing. "I am pleased to see the strong launch and commercial momentum across our core markets during the quarter. Our portfolio execution in branded markets of India and South Africa and strong respiratory traction driving our US generic franchise to a multi-quarter high quarter were key drivers," Cipla MD and Global CEO Umang Vohra noted. The unlocking of the company's first peptide asset, lanreotide injection is an important step in strengthening complex generics engine, inching up the drug .

Omicron spread: Pfizer seeks conditional EU authorisation for Covid-19 pill

The announcement comes as countries in much of the 27-nation bloc are reporting soaring numbers of infections

Brinton Pharma to launch generic version of anti-Covid pill Molnupiravir

The company will introduce it in the domestic market under the brand 'Molviton'

Pharma firm Venus Remedies makes the cut for PLI Scheme

Under this scheme, Venus Remedies will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products

Pharma major Lupin announces launch of its diagnostics business

Homegrown pharma major Lupin Ltd on Friday announced the launch of its diagnostics arm as part of its strategy to provide integrated healthcare in India.